Literature DB >> 19727113

Effects of angiotensin II receptor blockers on dementia.

Masaki Mogi1, Masatsugu Horiuchi.   

Abstract

The renin-angiotensin system (RAS) is involved in pathological mechanisms of target organ damage as well as the induction of hypertension; therefore, blockade of the RAS has been expected to prevent cardiovascular and cerebrovascular diseases beyond its antihypertensive effects. In spite of the well-characterized role of angiotensin (Ang) II receptor blockers (ARBs) in preventing the onset and recurrence of stroke, the clinical evidence for an effect of ARBs on dementia has not been definitive. However, preliminary experiments raise the possibility that treatment using ARBs may prevent ischemic brain damage and cognitive impairment. Moreover, recent reports have shown that some ARBs prevent amyloid beta deposition in the brain and attenuate cognitive impairment in Alzheimer disease models. Furthermore, recent cohort studies indicate that lower incidence of Alzheimer disease is observed in elderly individuals treated with ARBs. These results indicate a beneficial role for ARBs in cognitive impairment associated with vascular disease, Alzheimer disease, metabolic syndrome and other neurodegenerative diseases. Here, we review the effects of ARBs on the brain with a focus on dementia and future therapeutic approaches for elderly people suffering from disabilities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727113     DOI: 10.1038/hr.2009.110

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  22 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

2.  Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.

Authors:  Daniel A Nation; Jean Ho; Belinda Yew
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

3.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.

Authors:  Jessika Royea; Luqing Zhang; Xin-Kang Tong; Edith Hamel
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

4.  Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Begoña Villar-Cheda; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Maria J Guerra
Journal:  Aging Dis       Date:  2011-04-20       Impact factor: 6.745

5.  β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates.

Authors:  Jung-A A Woo; Tian Liu; Cenxiao C Fang; Maria A Castaño; Teresa Kee; Ksenia Yrigoin; Yan Yan; Sara Cazzaro; Jenet Matlack; Xinming Wang; Xingyu Zhao; David E Kang; Stephen B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

Review 6.  Angiotensin inhibition and longevity: a question of hydration.

Authors:  Simon N Thornton
Journal:  Pflugers Arch       Date:  2010-12-17       Impact factor: 3.657

7.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

8.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

Review 9.  Vascular dementia.

Authors:  Amos D Korczyn; Veronika Vakhapova; Lea T Grinberg
Journal:  J Neurol Sci       Date:  2012-05-08       Impact factor: 3.181

10.  The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease.

Authors:  Giuseppe Tosto; Thomas D Bird; David A Bennett; Bradley F Boeve; Adam M Brickman; Carlos Cruchaga; Kelley Faber; Tatiana M Foroud; Martin Farlow; Alison M Goate; Neill R Graff-Radford; Rafael Lantigua; Jennifer Manly; Ruth Ottman; Roger Rosenberg; Daniel J Schaid; Nicole Schupf; Yaakov Stern; Robert A Sweet; Richard Mayeux
Journal:  JAMA Neurol       Date:  2016-10-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.